Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics
JAMA · 2023
DOI: 10.1001/jama.2023.21958 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Alissa K Wong und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: Demography, Drug Approval, Neoplasms, Clinical Trials as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, FDA HHS.
Abstract (Originalsprache)
This study evaluates whether FDA-approved novel cancer therapeutics supported by pivotal trials with adequate representation of minoritized groups were associated with slower clinical development times than those with inadequate representation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
- Department of Epidemiology, Rollins School of Public Health, Atlanta, Georgia.
Förderung
- NCATS NIH HHS
- FDA HHS
Zitieren
APA
Wong, A. K., Miller, J. E., Mooghali, M., Ramachandran, R., Ross, J. S., & Wallach, J. D. (2023). Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics. JAMA. https://doi.org/10.1001/jama.2023.21958
Vancouver
Wong AK, Miller JE, Mooghali M, Ramachandran R, Ross JS, Wallach JD. Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics. JAMA. 2023. doi:10.1001/jama.2023.21958
BibTeX
@article{Wong2023,
author = {Wong, Alissa K and Miller, Jennifer E and Mooghali, Maryam and Ramachandran, Reshma and Ross, Joseph S and Wallach, Joshua D},
title = {Pivotal Trial Demographic Representation and Clinical Development Times for Oncology Therapeutics},
journal = {JAMA},
year = {2023},
doi = {10.1001/jama.2023.21958}
}
EUVIMED